An increasing body of evidence from recently published studies suggests that CFLAR overexpression contributes to tumor progression and correlates with a poor clinical outcome in cancers such as prostate, colorectal, gastric cancers, head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer, which may be related to the cell death inhibitory function of FLIP (81, 82). The gene discussed is CFLAR; the disease is non-small cell lung carcinoma.